PIONEER TEENS: Oral Semaglutide Posts Positive Phase 3 Results in Pediatric T2D
Published: April 24, 2026 · 4 min read · By Grey Peptides News Desk · ✓ Sourced
On April 23, Novo Nordisk reported positive topline results from PIONEER TEENS — a phase 3a trial of oral semaglutide in children and adolescents aged 10 to 17 with type 2 diabetes. The trial met its primary endpoint of superior HbA1c reduction versus placebo, and Novo says the safety profile was consistent with prior semaglutide trials. This is the first oral GLP-1 receptor agonist to post positive phase 3 data in this age group.
The trial
PIONEER TEENS (NCT06221969) enrolled pediatric patients aged 10–17 with type 2 diabetes and randomized them to oral semaglutide or placebo on top of background care. The primary endpoint was change in HbA1c — the standard measure of long-term glycemic control. Novo reported a statistically superior reduction in HbA1c on oral semaglutide compared to placebo, with a tolerability profile the company described as well-tolerated and consistent with its previous adult semaglutide programs.
The detailed trial results — specific HbA1c deltas, body-weight changes, and granular adverse-event rates — were not included in the topline announcement and will appear in a future peer-reviewed publication and at a scientific meeting.
The clinical context
Type 2 diabetes in children and adolescents has roughly tripled in incidence over the past two decades, but treatment options for this age group have remained narrow. Metformin and injectable liraglutide are FDA-approved for pediatric T2D; very little else is. Compared to adult-onset T2D, the pediatric form tends to progress faster and respond less robustly to lifestyle and metformin alone, which has left clinicians and families with limited next-line choices.
Injectable GLP-1 receptor agonists have shown efficacy in adolescent obesity and T2D trials, but the requirement for weekly or daily injection is a real adherence barrier in this population. An oral option that hits comparable glycemic targets — if approved for pediatric use — would meaningfully change what's available.
What the formulation looks like
Oral semaglutide is the same active ingredient as Ozempic and Wegovy, but reformulated with an absorption enhancer (SNAC, sodium N-(8-[2-hydroxybenzoyl]amino) caprylate) that allows the peptide to cross the gastric epithelium. Two bioequivalent tablet generations exist — 1.5/4/9 mg round tablets and 3/7/14 mg oval tablets — with higher 25 mg and 50 mg strengths approved in the EU for adult T2D. The 25 mg tablet is the basis of Wegovy pill, which the FDA approved for adult weight management in December 2025.
Oral semaglutide is currently marketed in the US as Rybelsus (T2D) and is launching as Ozempic pill later in Q2 2026.
What's next
Novo did not provide regulatory submission timing for the pediatric indication in its April 23 announcement. The standard path is full data presentation at a scientific meeting (likely ADA in June or EASD in September), peer-reviewed publication, then a supplemental indication filing with the FDA and EMA. A label expansion to pediatric T2D would be the first pediatric indication for any oral GLP-1 RA.
Related on Grey Peptides
Full profile: mechanism, all four FDA-approved formulations, evidence summary. Semaglutide vs Tirzepatide
Side-by-side comparison of the two leading GLP-1 RAs. Best Peptides for Fat Loss (2026)
Where oral semaglutide sits in the broader GLP-1 / GIP / glucagon landscape.
Novo Nordisk — PIONEER TEENS topline announcement ↗
Trial: PIONEER TEENS, NCT06221969. Bagsværd, Denmark, April 23, 2026.